Thus, the potential of targeting ICAM-1 to alter cisplatin sensitivity in OAC needs further exploration, as it has direct effects on numerous cell types, including both cancer and endothelial cells, and is reliant on interactions with the tumour microenvironment. Here, ICAM1 is linked to neoplasm.